Syndax Pharmaceuticals (SNDX) Competitors $15.40 -0.47 (-2.96%) Closing price 04:00 PM EasternExtended Trading$15.88 +0.48 (+3.12%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNDX vs. VKTX, CYTK, TGTX, KRYS, ACAD, PCVX, ADMA, ACLX, AAPG, and AKROShould you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Viking Therapeutics (VKTX), Cytokinetics (CYTK), TG Therapeutics (TGTX), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), Vaxcyte (PCVX), ADMA Biologics (ADMA), Arcellx (ACLX), Ascentage Pharma Group International (AAPG), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Syndax Pharmaceuticals vs. Its Competitors Viking Therapeutics Cytokinetics TG Therapeutics Krystal Biotech ACADIA Pharmaceuticals Vaxcyte ADMA Biologics Arcellx Ascentage Pharma Group International Akero Therapeutics Syndax Pharmaceuticals (NASDAQ:SNDX) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Does the media favor SNDX or VKTX? In the previous week, Viking Therapeutics had 10 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 24 mentions for Viking Therapeutics and 14 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.71 beat Viking Therapeutics' score of 0.36 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 5 Negative mention(s) 3 Very Negative mention(s) Neutral Which has more risk and volatility, SNDX or VKTX? Syndax Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Which has higher earnings & valuation, SNDX or VKTX? Viking Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Viking Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyndax Pharmaceuticals$77.93M17.02-$318.76M-$3.89-3.96Viking TherapeuticsN/AN/A-$109.96M-$1.53-15.92 Do institutionals & insiders hold more shares of SNDX or VKTX? 76.0% of Viking Therapeutics shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by insiders. Comparatively, 4.1% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts recommend SNDX or VKTX? Syndax Pharmaceuticals currently has a consensus price target of $38.00, suggesting a potential upside of 146.75%. Viking Therapeutics has a consensus price target of $86.92, suggesting a potential upside of 256.83%. Given Viking Therapeutics' higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Syndax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is SNDX or VKTX more profitable? Viking Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -428.48%. Viking Therapeutics' return on equity of -19.98% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syndax Pharmaceuticals-428.48% -130.47% -56.12% Viking Therapeutics N/A -19.98%-19.38% SummaryViking Therapeutics beats Syndax Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNDX vs. The Competition Export to ExcelMetricSyndax PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.33B$3.06B$5.76B$9.65BDividend YieldN/A2.22%3.91%4.09%P/E Ratio-3.9620.6130.7825.12Price / Sales17.02358.53457.76157.42Price / CashN/A41.5625.2228.45Price / Book4.569.509.365.94Net Income-$318.76M-$54.72M$3.26B$265.56M7 Day Performance18.74%2.39%1.83%0.95%1 Month Performance62.79%4.60%3.69%2.47%1 Year Performance-24.88%9.11%28.88%20.24% Syndax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNDXSyndax Pharmaceuticals4.0456 of 5 stars$15.40-3.0%$38.00+146.8%-20.4%$1.33B$77.93M-3.96110News CoverageInsider TradeVKTXViking Therapeutics3.9932 of 5 stars$39.90-3.3%$86.92+117.8%-25.8%$4.48BN/A-26.0720Trending NewsAnalyst ForecastOptions VolumeGap DownCYTKCytokinetics3.5743 of 5 stars$37.33+1.2%$71.58+91.8%-31.1%$4.48B$85.74M-7.35250TGTXTG Therapeutics4.4705 of 5 stars$27.77-0.4%$46.25+66.6%+25.6%$4.41B$329M75.16290Positive NewsKRYSKrystal Biotech4.711 of 5 stars$148.24-0.7%$210.75+42.2%-24.0%$4.31B$290.52M30.24210Positive NewsACADACADIA Pharmaceuticals3.9202 of 5 stars$24.59-2.1%$28.88+17.4%+62.7%$4.15B$957.80M18.52510Positive NewsAnalyst UpgradePCVXVaxcyte2.1664 of 5 stars$31.67+0.4%$136.50+331.0%-59.3%$4.11BN/A-7.70160ADMAADMA Biologics4.4296 of 5 stars$16.91-1.7%$27.67+63.7%+0.5%$4.04B$426.45M19.67530ACLXArcellx1.8994 of 5 stars$70.73-0.4%$114.31+61.6%+10.0%$3.93B$56.98M-20.7180News CoverageAAPGAscentage Pharma Group InternationalN/A$42.20+2.6%N/AN/A$3.92B$980.65M0.00600AKROAkero Therapeutics3.9324 of 5 stars$48.76+0.9%$81.57+67.3%+95.5%$3.91BN/A-24.4130Analyst Upgrade Related Companies and Tools Related Companies VKTX Alternatives CYTK Alternatives TGTX Alternatives KRYS Alternatives ACAD Alternatives PCVX Alternatives ADMA Alternatives ACLX Alternatives AAPG Alternatives AKRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNDX) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access